TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 28343236
Drug: Chloride-limited fluid
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chloride-limited fluid strategy (buffered salt solution and 20% albumin)
Study: 28343449
Drug: Severe iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Severe iron loading with very low T2* of 5.0 ± 2.0 ms (iron concentration 8.5 ± 7.0 mg/g dw) and diffuse granular myocardial iron deposition.
Study: 28345157
Drug: 0.5 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg/day entecavir maleate
Study: 28346229
Drug: Autologous hematopoietic
Normalized name: Autologous Hematopoietic Peripheral Blood Stem Cells
DrugBank: Autologous Hematopoietic Peripheral Blood Stem Cells (DB17067)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Autologous hematopoietic stem cell transplantation with gene-modified CD34+ cells (MND-ADA) after busulfan conditioning (90 mg/m2) and ERT cessation
Study: 28346714
Drug: ELISA (>0.35
Approvals — FDA: no, EMA: no, PMDA: no
Description: ELISA (>0.35 μg/ml)
Study: 28347564
Drug: Walnuts (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Walnuts (30 g/d)
Study: 28347564
Drug: Pomegranate extract
Normalized name: Pomegranate Extract
DrugBank: Pomegranate (DB14317)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pomegranate extract (450 mg/d)
Study: 28347564
Drug: Nuts (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nuts (15 g-walnuts, 7.5 g-hazelnuts and 7.5 g-almonds/d)
Study: 28349167
Drug: ABT-414 (1-4
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABT-414 (1-4 mg/kg once every 3 weeks or 1 or 1.5 mg/kg weekly for 2 out of every 3 weeks)
Study: 28349167
Drug: ABT-414 (doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABT-414 (doses ≥2 mg/kg)
Study: 28349262
Drug: β-alanine supplementation
Normalized name: Alanine
DrugBank: Alanine (DB00160)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: β-alanine supplementation (6.4 g/day for 28 days)
Study: 28351345
Drug: 3 × treatment arm
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 × treatment arm (three annual rounds of MDA with azithromycin)
Study: 28351345
Drug: 1 × treatment arm
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 × treatment arm (one round of MDA)
Study: 28351842
Drug: Intracoronary infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intracoronary infusion of autologous bone marrow-derived mononuclear cells (BMCs)
Study: 28353191
Drug: Certolizumab pegol
Normalized name: Certolizumab Pegol
DrugBank: Certolizumab pegol (DB08904)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Certolizumab pegol (CZP) 400 mg every 4 weeks (Q4W) monotherapy
Study: 28353191
Drug: Certolizumab pegol
Normalized name: Certolizumab Pegol
DrugBank: Certolizumab pegol (DB08904)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Certolizumab pegol (CZP) 400 mg every 4 weeks (Q4W) in combination with methotrexate (MTX)
Study: 28355434
Drug: Apixaban therapy
Normalized name: Apixaban
DrugBank: Apixaban (DB06605)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Apixaban therapy
Study: 28356179
Drug: Dexmedetomidine (DEX)
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexmedetomidine (DEX) sedation at a dose of 2 μg/kg/h
Study: 28356275
Drug: Konjac glucomannan,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Konjac glucomannan, a viscous soluble fiber, dosage and duration not specified
Study: 28356282
Drug: Ticagrelor 180
Normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ticagrelor 180 mg loading dose (LD)
Study: 28356282
Drug: Clopidogrel 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel 600 mg loading dose (LD)
Study: 28356440
Drug: Medical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical treatment for stenosis with a high FFR (≥0.76)
Study: 28357727
Drug: BEZ235 (dactolisib)
Normalized name: Dactolisib
DrugBank: Dactolisib (DB11651)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BEZ235 (dactolisib) at doses of 200, 400, and 800 mg daily along with everolimus at 2.5 mg daily in 28-day cycles
Study: 28357772
Drug: Once-daily injected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily injected GLP1 agonist lixisenatide (Lixi) and basal insulin analogue glargine (iGlar)
Study: 28359201
Drug: Adjunctive Vagus
Normalized name: Sus scrofa vagus nerve preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjunctive Vagus Nerve Stimulation (VNS)
Study: 28359318
Drug: Combined targeted
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined targeted therapy bevacizumab and erlotinib (BE)
Study: 28360015
Drug: Etirinotecan pegol
Normalized name: Etirinotecan pegol
DrugBank: Etirinotecan pegol (DB14951)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etirinotecan pegol (145 mg/m2)
Study: 28363360
Drug: Vaccine administration
Normalized name: Japanese encephalitis virus vaccine, inactivated
DrugBank: Japanese Encephalitis Virus Vaccine Inactivated (DB19294)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaccine administration
Study: 28363682
Drug: Oral anticoagulation
Normalized name: monitoring agent for oral anticoagulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral anticoagulation (OAC) during PCI-S
Study: 28363827
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of predictive parameters (DAS28, IFN score, DMARD use)
Study: 28364214
Drug: Robust patients
Normalized name: Shorea robusta resin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Robust patients receiving chemotherapy
Study: 28364381
Drug: Adalimumab with
Normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Adalimumab with low-dose MTX (<8 mg/week)
Study: 28364381
Drug: Adalimumab with
Normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Adalimumab with high-dose MTX (≥8 mg to ≤16 mg/week)
Study: 28365080
Drug: Nutrition therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nutrition therapy (NT)
Study: 28366306
Drug: l-arginine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: l-arginine infusion
Study: 28366342
Drug: Rotigotine transdermal
Normalized name: Rotigotine Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rotigotine transdermal system (0.5, 1, 2, 3 mg/24 h) applied daily and up-titrated weekly.
Study: 28367260
Drug: Intradermal injection
Normalized name: Dryvax Intradermal Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradermal injection of Botulinum Toxin A
Study: 28367260
Drug: Intramuscular injection
Normalized name: rabies, intramuscular injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular injection of Botulinum Toxin A
Study: 28368443
Drug: Continuous kisspeptin
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous kisspeptin infusion (12.5 µg/kg/h) over 24 hours
Study: 28368443
Drug: Kisspeptin (0.313
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kisspeptin (0.313 µg/kg) and GnRH (75 ng/kg) intravenous boluses
Study: 28368743
Drug: IV VRC01
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV VRC01 (10, 20, 30 or 40 mg/kg) every 4 or 8 weeks
Study: 28368743
Drug: SC VRC01
Approvals — FDA: no, EMA: no, PMDA: no
Description: SC VRC01 (5 mg/kg) every 2 weeks
Study: 28368743
Drug: 10 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg/kg 8-weekly regimen
Study: 28368743
Drug: 30 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg/kg 8-weekly regimen
Study: 28369329
Drug: Vedolizumab 300
Normalized name: vedolizumab 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vedolizumab 300 mg intravenously (IV) every 4 weeks
Study: 28369415
Drug: Tenofovir alafenamide
Normalized name: Tenofovir Alafenamide
DrugBank: Tenofovir alafenamide (DB09299)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Tenofovir alafenamide 5 mg
Study: 28369415
Drug: Tenofovir alafenamide
Normalized name: Tenofovir Alafenamide
DrugBank: Tenofovir alafenamide (DB09299)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Tenofovir alafenamide 10 mg
Study: 28369415
Drug: Tenofovir alafenamide
Normalized name: Tenofovir Alafenamide
DrugBank: Tenofovir alafenamide (DB09299)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Tenofovir alafenamide (all doses)
Study: 28369415
Drug: Tenofovir alafenamide
Normalized name: Tenofovir Alafenamide
DrugBank: Tenofovir alafenamide (DB09299)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Tenofovir alafenamide dosing in vivo
Study: 28370350
Drug: Daclatasvir/asunaprevir/beclabuvir (DCV-TRIO)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daclatasvir/asunaprevir/beclabuvir (DCV-TRIO) 30 mg, 200 mg, and 75 mg respectively, administered twice daily for 12 weeks.
Study: 28373005
Drug: Avelumab monotherapy
Normalized name: Avelumab
DrugBank: Avelumab (DB11945)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Avelumab monotherapy 10 mg/kg every 2 weeks until disease progression or toxicity
Study: 28373007
Drug: Avelumab 1
Normalized name: Avelumab
DrugBank: Avelumab (DB11945)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Avelumab 1 mg/kg
Study: 28373007
Drug: Avelumab 3
Normalized name: Avelumab
DrugBank: Avelumab (DB11945)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Avelumab 3 mg/kg
Study: 28373007
Drug: Avelumab 20
Normalized name: avelumab 20 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Avelumab 20 mg/kg
Study: 28373007
Drug: Avelumab (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Avelumab (all doses)
Study: 28373007
Drug: Avelumab (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Avelumab (10 mg/kg and 20 mg/kg)
Study: 28373007
Drug: Avelumab (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Avelumab (3 mg/kg and 10 mg/kg)
Study: 28373262
Drug: Ibrutinib at
Normalized name: Ibrutinib
DrugBank: Ibrutinib (DB09053)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ibrutinib at a once-daily dose of 420 mg
Study: 28373262
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (lower dose intensity)
Study: 28374496
Drug: Entecavir hydrate
Normalized name: entecavir anhydrous
DrugBank: Entecavir (DB00442)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Entecavir hydrate (ETV) 0.5 mg
Study: 28375658
Drug: Empagliflozin/linagliptin single-pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Empagliflozin/linagliptin single-pill combination therapy
Study: 28375658
Drug: Empagliflozin or
Normalized name: empagliflozin Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Empagliflozin or linagliptin as first-line treatment
Study: 28376316
Drug: Nadroparin added
Normalized name: nadroparin
DrugBank: Nadroparin (DB08813)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nadroparin added to chemotherapy
Study: 28376739
Drug: Seroprevalence of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Seroprevalence of Bordetella pertussis antibodies in adults
Study: 28377958
Drug: 10 or
Normalized name: K-10 Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 or 25 μg vitamin D supplementation
Study: 28378544
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg omeprazole orally once daily for 8 days
Study: 28379427
Drug: Liraglutide 0.6
Normalized name: liraglutide 0.6 mg/0.1 mL (18 mg/3 mL) SUBCUT PEN INJECTOR (ML)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liraglutide 0.6 mg once daily subcutaneously for 21 days
Study: 28381249
Drug: Point-of-care alert
Approvals — FDA: no, EMA: no, PMDA: no
Description: Point-of-care alert for cardioprotective medications
Study: 28381434
Drug: Microscopic observation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Microscopic observation drug susceptibility assay
Study: 28382208
Drug: Etravirine 200
Normalized name: etravirine 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etravirine 200 mg bid with ≥1 other active antiretroviral (excluding darunavir/ritonavir)
Study: 28382379
Drug: Erlotinib with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erlotinib with concurrent and sequential radiotherapy
Study: 28383392
Drug: Valganciclovir, 17
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valganciclovir, 17 mg/kg once daily
Study: 28383677
Drug: Pazopanib 800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pazopanib 800 mg/day until disease progression or unacceptable toxicity
Study: 28384199
Drug: Direct anticoagulants
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Direct anticoagulants (DOAC)
Study: 28385065
Drug: Raltegravir (RAL)
DrugBank: Raltegravir (DB06817)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Raltegravir (RAL) 400 mg BID
Study: 28386037
Drug: Artificial intelligence
Normalized name: Intelence
DrugBank: Etravirine (DB06414)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Artificial intelligence platform for daily monitoring
Study: 28386037
Drug: No daily
Normalized name: Aveeno Daily Moisturizing
DrugBank: Dimethicone (DB11074)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: No daily monitoring (control)
Study: 28387632
Drug: Second-window indocyanine
Normalized name: Indocyanine Green
DrugBank: Indocyanine green (DB16024)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Second-window indocyanine green (ICG) 5 mg/kg injected the day prior to surgery
Study: 28388956
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg of prednisolone for 3 days (days 3-5) along with 1 g of paracetamol per day for 5 days for pain relief.
Study: 28388956
Drug: Pred-test (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pred-test (20 mg of prednisolone for 3 days)
Study: 28389304
Drug: Inhaled corticosteroid
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled corticosteroid (ICS) with add-on therapy
Study: 28389462
Drug: High-dose araC
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose araC (HD-araC) used in the second induction cycle
Study: 28390410
Drug: Pentasa® 4000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentasa® 4000 mg/day in 2 divided doses
Study: 28390410
Drug: Asacol® 3600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Asacol® 3600 mg/day in 3 divided doses
Study: 28390437
Drug: Medication overuse
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Medication overuse headache (MOH) patients
Study: 28391235
Drug: Postoperative serum
Normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative serum albumin drop (ΔAlb) ≥10 g/L on postoperative day 1 (POD 1)
Study: 28391409
Drug: Comprehensive medication
Normalized name: Easy Care First Aid Kit - Comprehensive KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comprehensive medication reviews conducted by clinical pharmacists
Study: 28391409
Drug: Comprehensive medication
Normalized name: Easy Care First Aid Kit - Comprehensive KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comprehensive medication reviews conducted by clinical pharmacists (after adjustment for heart failure)
Study: 28391409
Drug: Post-hoc analysis
Normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Post-hoc analysis of comprehensive medication reviews
Study: 28393103
Drug: PICOPREP tailored
Approvals — FDA: no, EMA: no, PMDA: no
Description: PICOPREP tailored dosing
Study: 28393103
Drug: PICOPREP day-before
Approvals — FDA: no, EMA: no, PMDA: no
Description: PICOPREP day-before dosing
Study: 28393673
Drug: Pantheris +
Normalized name: Amanita pantherina whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pantheris + adjunctive therapy
Study: 28394435
Drug: Non-anticoagulant treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-anticoagulant treatment
Study: 28395880
Drug: Lymphodepleting chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lymphodepleting chemotherapy (intravenous cyclophosphamide [60 mg/kg] daily for 2 days followed by fludarabine [25 mg/m2])
Study: 28395880
Drug: Lymphodepleting chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lymphodepleting chemotherapy
Study: 28397471
Drug: High Hcy
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High Hcy and MTHFR1298AC + CC genotypes
Study: 28397698
Drug: Ledipasvir-sofosbuvir once
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ledipasvir-sofosbuvir once daily for 6 weeks
Study: 28399802
Drug: Isoniazid (INH)
Normalized name: Isoniazid
DrugBank: Isoniazid (DB00951)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isoniazid (INH) with rifapentine once weekly for 12 weeks (INH/RPT-3)
Study: 28399802
Drug: 6 months
Normalized name: leuprolide 45 mg/6 months intramuscular kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 months of daily INH (INH-6)
Study: 28399802
Drug: 9 months
Normalized name: treprostinil
DrugBank: Treprostinil (DB00374)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 9 months of daily INH (INH-9)
Study: 28399802
Drug: 3-4 months
Normalized name: treprostinil
DrugBank: Treprostinil (DB00374)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 3-4 months daily INH plus rifampicin (INH/RFMP 3-4)
Study: 28399802
Drug: 4 months
Normalized name: leuprolide 30 mg/4 months intramuscular kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 months daily rifampicin alone (RFMP-4)
Study: 28399804
Drug: Abacavir-containing treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abacavir-containing treatment
Study: 28399850
Drug: General Oral
Normalized name: Generlac Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: General Oral Health Assessment Index (GOHAI)
Study: 28399921
Drug: Endocrine therapy
Normalized name: ENDOCRINE THERAPY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endocrine therapy + dasatinib (p-Src kinase inhibitor)
Study: 28399931
Drug: Biologic CTP
Normalized name: CTP-SOMATROPIN FUSION PROTEIN
DrugBank: Somatrogon (DB14960)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: Biologic CTP (IL1 inhibitor [IL1i] ± GC, IL6 inhibitor [IL6i] ± GC)
Study: 28400218
Drug: Heparin-coated stent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin-coated stent grafts
Study: 28402487
Drug: serum klotho
Normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
Approvals — FDA: no, EMA: no, PMDA: no
Description: serum klotho (seKL) ≥280 ng/L
Study: 28402487
Drug: serum klotho
Normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
Approvals — FDA: no, EMA: no, PMDA: no
Description: serum klotho (seKL) <280 ng/L
Study: 28403013
Drug: V2 receptor
Normalized name: rhuFab V2
DrugBank: Ranibizumab (DB01270)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: V2 receptor blockade
Study: 28403013
Drug: Changes in
Normalized name: guaifenesin / hydrocodone bitartrate Oral Solution [Canges XP]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Changes in daily water intake
Study: 28403055
Drug: PHiD-CV vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PHiD-CV vaccine administered to children <6 months (3 primary doses + booster)
Study: 28403055
Drug: PHiD-CV vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PHiD-CV vaccine administered to children 7-11 months (2 primary doses + booster)
Study: 28403055
Drug: PHiD-CV vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PHiD-CV vaccine administered to children 12-23 months (2 catch-up doses)
Study: 28403119
Drug: Combined measurement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined measurement of soluble ST2 (≥ 500 ng/mL) and amino-terminal pro-B-type natriuretic peptide (≥ 4,500 ng/L) at 12 hours
Study: 28403822
Drug: Education about
Normalized name: reductic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Education about realistic expectations for chronic pain management and therapy options
Study: 28404672
Drug: Mycobacterium tuberculosis
Normalized name: MYCOBACTERIUM TUBERCULOSIS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mycobacterium tuberculosis mutations conferring resistance to second-line antituberculous drugs
Study: 28405328
Drug: Photodynamic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Photodynamic therapy (PDT) using polyhematoporphyrin
Study: 28405470
Drug: Sensitivity and
Normalized name: STANNOUS FLUORIDE 1.1 mg in 1 g ORAL PASTE [SENSODYNE Sensitivity and Gum Mint]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sensitivity and specificity of VEGF concentration at the optimal cut-off of 713 pg/mL applied to the whole cohort
Study: 28405472
Drug: jSpA treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: jSpA treatment (exact intervention not specified)
Study: 28405473
Drug: Baricitinib 2
Normalized name: baricitinib 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baricitinib 2 mg QD
Study: 28405473
Drug: Baricitinib 4
Normalized name: baricitinib 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baricitinib 4 mg QD
Study: 28406555
Drug: Clinical and
Normalized name: DuoCare Clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clinical and biological predictors of disease course and outcome in GBS
Study: 28406674
Drug: Caffeine (exact
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (exact dosage and duration not specified)
Study: 28407138
Drug: After treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: After treatment of acromegaly
Study: 28407492
Drug: Discontinuation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Discontinuation of anticoagulation in patients without RVT and negative D-dimer
Study: 28408121
Drug: Live attenuated
Normalized name: mumps, live attenuated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Live attenuated influenza vaccine (LAIV4)
Study: 28408462
Drug: CD19 CAR
Normalized name: CAR.CD19-Redirected T cells
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CD19 CAR T cells of defined formulation and dose
Study: 28410572
Drug: Internal fixation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internal fixation with prophylactic antibiotics (intra-operative: 92.1%, post-operative: 96.8%)
Study: 28410572
Drug: Internal fixation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Internal fixation with antibiotics prescribed for an average of 8.3 days for closed fractures and 9.1 days for open fractures
Study: 28413427
Drug: RSV F
Normalized name: Respiratory syncytial virus fusion protein.
Approvals — FDA: no, EMA: no, PMDA: no
Description: RSV F nanoparticle vaccine (60 or 90 μg RSV F protein, with or without aluminum phosphate adjuvant) administered concurrently with TIV
Study: 28413427
Drug: RSV F
Normalized name: Respiratory syncytial virus fusion protein.
Approvals — FDA: no, EMA: no, PMDA: no
Description: RSV F nanoparticle vaccine (60 or 90 μg RSV F protein, with or without aluminum phosphate adjuvant)